Phase
Condition
Breast Cancer
Vaginal Cancer
Cancer
Treatment
Psilocybin
Clinical Study ID
Ages > 21 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
1, Aged ≥ 21 2. Diagnosis of:
early-stage breast cancer at low risk of recurrence
defined as clinical stage 1 or 2
completed primary treatment (surgery, chemotherapy [adjuvant, patients maycontinue to be treated with neoadjuvant], and/or radiation) > 6 months ago
oncologist reported risk of recurrence at 10 years < 20%
late-stage ovarian cancer at high risk of recurrence
defined as Clinical stage 3 or 4
currently in remission
oncologist reported risk of recurrence at 10 years > 80% 2. Functional Statusdefined as:
Eastern Cooperative Oncology Group (ECOG) ≤1
Palliative Performance Scale (PPS) ≥60%
Ability to tolerate PO medication administration 4. Fear of recurrence at screeningand baseline 5. Have an identified support person
Agree to be accompanied home (or to an otherwise safe destination) by the supportperson, or another responsible party, following dosing 6. Participants ofchildbearing potential must agree to practice an effective means of birth controlthroughout the duration of the study.
Exclusion
Exclusion Criteria:
- Unstable medical conditions or serious abnormalities of complete blood count,chemistries, or EKG that in the opinion of the study physician would preclude safeparticipation in the trial. Some examples include:
Congestive heart failure
Valvular heart disease
Clinically significant arrhythmias (e.g., ventricular fibrillation, torsades)or clinically significant EKG abnormality (i.e., QTC interval > 450)
Recent acute myocardial infarction or evidence of ischemia
Malignant hypertension
Congenital long QT syndrome
Acute renal failure
Severe hepatic impairment
Respiratory failure
eGFR < 50 mL/min/1.73m2
LFTs > 1.5 x ULN
WBC < 5 x 10*9/L
Hemoglobin < 8.0 g/dL
Platelets < 150 x 10*9/L
Risk for hypertensive crisis defined as: Screening, Baseline, Medication session (predose) blood pressure >140/90 mmHg
Significant central nervous system (CNS) pathology Examples include:
Primary or secondary cerebral neoplasm
Epilepsy
History of stroke
Cerebral aneurysm
Dementia
Delirium
- Primary psychotic or affective psychotic disorders Examples include current or pastDSM-5 criteria for:
Schizophrenia spectrum disorders
Schizoaffective disorder
Bipolar I or bipolar II disorder
Major Depressive Disorder with psychotic features
Prior history of psychosis due to medical condition or substance use
- Family history of psychotic or serious bipolar spectrum illnesses. Examples include first-degree relative with:
Schizophrenia spectrum disorders
Schizoaffective disorder
Bipolar I disorder with psychotic features
- High risk of adverse emotional or behavioral reaction based on investigator'sclinical evaluation and judgement. Examples include:
Agitation
Violent behavior
- Active substance use disorders (SUDs) defined as:
DSM-5 criteria for moderate or severe alcohol or drug use disorder (excludingcaffeine and nicotine) within the past year
DAST-10 score of 3 or higher
Two or more "yes" responses to CAGE screening questionnaire
- Extensive use of serotonergic hallucinogens (e.g., LSD, psilocybin) defined as:
Any use in the last 12 months
>25 lifetime uses
- Clinically significant suicidality or high risk of completed suicide defined as:
'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months atScreening or 'since last visit' at Baseline
Any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following onthe C-SSRS: actual attempt, interrupted attempt, aborted attempt, orpreparatory acts
Have any suicidal ideation or thoughts, in the opinion of the study physicianor PI, that presents a serious risk of suicidal or self-injurious behavior
History of hallucinogen persisting perception disorder (HPPD)
Pregnancy/lactation
Cognitive impairment as defined by:
• Montreal Cognitive Assessment Test (MoCA) < 23
- Concurrent Medications
Antidepressants
Centrally-acting serotonergic agents (e.g., MAO inhibitors)
Serotonin-acting dietary supplements (such as 5-hydroxy-tryptophan or St.John's wort)
Antipsychotics (e.g., first and second generation)
Mood stabilizers (e.g., lithium, valproic acid)
Aldehyde dehydrogenase inhibitors (e.g., disulfiram)
Significant inhibitors of UGT 1A0 or UGT 1A10
Efavirenz
Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine,Benzodiazepines, Cocaine, Cannabis, Methamphetamine, MDMA, Methadone, Opiates (Morphine, Oxycodone), and Phencyclidine (PCP).
Have a psychiatric condition judged to be incompatible with establishment of rapportwith the study therapists or safe exposure to psilocybin
Have any psychological or physical symptom, medication, or other relevant finding ,based on the clinical judgment of the PI or relevant clinical study staff that wouldmake a participant unsuitable for the study.
Have an allergy or intolerance to any of the materials contained in the drug product
Non-English speaking individual
Be enrolled in another clinical trial assessing intervention(s) for anxiety,depression, and/or existential distress (e.g., pharmacologic or psychotherapeuticinterventions)
Study Design
Connect with a study center
Outpatient CTRC
Aurora, Colorado 80045
United StatesActive - Recruiting
University of Colorado Cancer Center
Aurora, Colorado 80045
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.